cannabis indica

DII — Doença de Crohn

termo de indexação original: IBD - Crohn's Disease

O acervo do Cannabis Indica reúne 75 estudos científicos que tocam a condição DII — Doença de Crohn, publicados entre 2004 e 2023. Pela leitura automatizada, 58 (77%) foram classificados como favoráveis, 11 (15%) como inconclusivos e 6 (8%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (43 estudos), seguido de estudo em animais (11). Os compostos mais presentes são Anandamida (AEA), 2-Araquidonoilglicerol (2-AG) e Hidrolase de Amidas de Ácidos Graxos (FAAH). Aparece com frequência ao lado de DII — Doença Inflamatória Intestinal, Síndrome do Intestino Irritável e Inflamação.

Estudos indexados
75
Período coberto
2004–2023
Favoráveis
58 · 77%
Inconclusivos
11 · 15%
Desfavoráveis
6 · 8%
Termo original
IBD - Crohn's Disease

O acervo em números

Tipo de estudo

Metanálise43
Estudo em Animais11
Ensaio Clínico8
Estudo Laboratorial5
Ensaio Clínico Duplo-Cego5
Metanálise Clínica3

Direção do resultado

Favorável58
Inconclusivo11
Desfavorável6

Por década

2000s5
2010s43
2020s27

75 estudos

Filtrar e buscar no acervo →
  1. 2023

    A Case of Panic Attacks Developing After 10 Years of Chronic Cannabis Use in a Patient With No Prior Psychiatric History

    DesfavorávelMetanáliseDorCâncerInflamaçãoTetraidrocanabinol (THC)Canabigerol (CBG)+13
  2. 2023

    Biotechnological Fungal Platforms for the Production of Biosynthetic Cannabinoids

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoTetraidrocanabinol (THC)THC Farmacêutico+25
  3. 2023

    Cannabidiol safety considerations: Development of a potential acceptable daily intake value and recommended upper intake limits for dietary supplement use

  4. 2023

    Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance

    FavorávelMetanáliseCâncerInflamaçãoAnsiedadeCanabigerol (CBG)Canabinol (CBN)+20
  5. 2023

    Medical Cannabis Received by Patients According to Qualifying Condition in a US State Cannabis Program: Product Choice, Dosing, and Age-Related Trends

    FavorávelMetanáliseDorCâncerDor — CrônicaTHC FarmacêuticoCBD Farmacêutico+16
  6. 2022

    Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors

  7. 2022

    Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico

  8. 2022

    Cannabinoid Receptor 2 (CB2) Inverse Agonist SMM-189 Induces Expression of Endogenous CB2 and Protein Kinase A That Differentially Modulates the Immune Response and Suppresses Experimental Colitis

  9. 2022

    Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    FavorávelMetanálise ClínicaDII — Doença Inflamatória Intestinal
  10. 2022

    Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review

  11. 2022

    Increased expression of CB2 receptor in the intestinal biopsies of children with inflammatory bowel disease

  12. 2022

    Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies

  13. 2022

    Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives

  14. 2022

    Role of cannabis in inflammatory bowel diseases

  15. 2022

    Shifting the Paradigm on Cannabis Safety

    DesfavorávelMetanáliseCâncerInflamaçãoEfeitos Adversos da CannabisCBD Farmacêutico+16
  16. 2022

    Urinary Cannabis Metabolite Concentrations in Cannabis Hyperemesis Syndrome

  17. 2021

    A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019

    InconclusivoMetanáliseDorCâncerDor — CrônicaTHC FarmacêuticoCBD Farmacêutico+9
  18. 2021

    Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes

  19. 2021

    Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

    InconclusivoEnsaio ClínicoDII — Doença Inflamatória Intestinal
  20. 2021

    Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review

  21. 2021

    Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn's disease, a randomized controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDII — Doença Inflamatória IntestinalQualidade de Vida
  22. 2021

    Symptoms and Extraintestinal Manifestations in Active Cannabis Users with Inflammatory Bowel Disease

    InconclusivoMetanáliseDII — Doença Inflamatória Intestinal
  23. 2020

    An Overview of Cannabis Based Treatment in Crohn's Disease

  24. 2020

    Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse

    FavorávelMetanáliseDII — Doença Inflamatória Intestinal
  25. 2020

    Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study

  26. 2020

    Resveratrol attenuates high-fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system

  27. 2020

    Small bowel intussusception in marijuana users

    DesfavorávelMetanáliseDorEfeitos Adversos da CannabisDor — Crônica+6
  28. 2019

    A Novel Standardized Cannabis sativa L. Extract and Its Constituent Cannabidiol Inhibit Human Polymorphonuclear Leukocyte Functions

    FavorávelEstudo LaboratorialDorInflamaçãoDoenças Cardiovasculares (DCV)+7
  29. 2019

    A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis

    FavorávelEnsaio Clínico Duplo-CegoDII — Doença Inflamatória IntestinalDII — Retocolite Ulcerativa
  30. 2019

    A systematic review of cannabidiol dosing in clinical populations

    FavorávelMetanálise ClínicaDorDependência — CannabisAnsiedade+14
  31. 2019

    Association Between Cannabis Use and Complications Related to Crohn's Disease: A Retrospective Cohort Study

    FavorávelMetanálise
  32. 2019

    Association between cannabis use and complications related to ulcerative colitis in hospitalized patients

  33. 2019

    Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease

    InconclusivoMetanálise
  34. 2019

    Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.

  35. 2019

    Cannabinoid Attenuation of Intestinal Inflammation in Chronic SIV-Infected Rhesus Macaques Involves T Cell Modulation and Differential Expression of Micro-RNAs and Pro-inflammatory Genes

  36. 2019

    Cannabis for the Treatment of Crohn's Disease and Ulcerative Colitis: Evidence From Cochrane Reviews

  37. 2019

    Cannabis for the treatment of ulcerative colitis

  38. 2019

    Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDII — Doença Inflamatória IntestinalDII — Retocolite Ulcerativa
  39. 2019

    Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls

  40. 2019

    Insights into the role of cannabis in the management of inflammatory bowel disease

  41. 2019

    Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer

  42. 2019

    Use of Cannabis in Gastroenterological and Hepatic Disorders

  43. 2018

    Cannabis and pediatric inflammatory bowel disease: change blossoms a mile high.

  44. 2018

    Cannabis for the treatment of Crohn's disease

    InconclusivoMetanálise
  45. 2018

    Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation.

  46. 2018

    The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn's and Colitis Foundation.

  47. 2017

    Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.

  48. 2017

    Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease

  49. 2017

    Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

  50. 2017

    Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial

    InconclusivoEnsaio Clínico Duplo-CegoDII — Doença Inflamatória IntestinalSíndrome do Intestino Irritável
  51. 2017

    Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.

  52. 2017

    Prevalence and Patterns of Marijuana Use in Young Adults With Inflammatory Bowel Disease.

  53. 2017

    Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges.

  54. 2016

    An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse.

  55. 2016

    Cannabis - the Israeli perspective

  56. 2016

    Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review.

  57. 2016

    The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease.

  58. 2016

    Therapeutic Use of Cannabis in Inflammatory Bowel Disease.

  59. 2015

    Comparison of Antispasmodic Effects of Dracocephalum Kotschyi Essential Oil, Limonene and α-Terpineol

    FavorávelEstudo em AnimaisDII — Doença Inflamatória Intestinal
  60. 2015

    Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases

    DesfavorávelMetanálise ClínicaDII — Doença Inflamatória IntestinalDII — Retocolite Ulcerativa
  61. 2014

    Cannabis for inflammatory bowel disease.

  62. 2014

    Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease

    DesfavorávelMetanálise
  63. 2014

    Geraniol-a Flavoring Agent With Multifunctional Effects in Protecting the Gastric and Duodenal Mucosa

  64. 2014

    Intestinal Fatty Acid Binding Protein (I-FABP) as a Promising Test for Crohn's Disease: A Preliminary Study

    FavorávelEnsaio ClínicoInflamaçãoProteína Ligadora de Ácidos Graxos (FABP)
  65. 2013

    Cannabidiol in inflammatory bowel diseases: a brief overview.

  66. 2013

    Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study

    FavorávelEnsaio Clínico Duplo-CegoDII — Doença Inflamatória IntestinalSíndrome do Intestino Irritável
  67. 2012

    Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study

    FavorávelEnsaio ClínicoInflamaçãoSíndrome do Intestino Irritável
  68. 2012

    The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity

  69. 2011

    The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease

  70. 2011

    Treatment of Crohn's Disease With Cannabis: An Observational Study

    FavorávelMetanáliseDII — Doença Inflamatória Intestinal
  71. 2008

    Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.

  72. 2008

    Targeting the endocannabinoid system: to enhance or reduce?

  73. 2008

    Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide

  74. 2007

    Cannabinoid Type 1 Receptor Modulates Intestinal Propulsion by an Attenuation of Intestinal Motor Responses Within the Myenteric Part of the Peristaltic Reflex

  75. 2004

    Involvement of cannabinoid receptors in gut motility and visceral perception

Continue por aqui

Perguntas frequentes

Quantos estudos sobre dii — doença de crohn estão indexados no acervo?
São 75 estudos, publicados entre 2004 e 2023. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 43 · Estudo em Animais: 11 · Ensaio Clínico: 8 · Estudo Laboratorial: 5 · Ensaio Clínico Duplo-Cego: 5 · Metanálise Clínica: 3. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 58 favoráveis, 11 inconclusivos e 6 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. DII — Doença de Crohn — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/dii-doenca-de-crohn/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). DII — Doença de Crohn — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/dii-doenca-de-crohn/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.